Article By:
ChinaBio® Today
Saturday, February 1, 2020 5:24 PM EDT
Sorrento Therapeutics, a San Diego-Nanjing-Suzhou biopharma, rejected a $7 per share take-private offer from an unnamed PE company that valued the company at $933 million. Sorrento reported a loss of $57 million over the last 12 months.